Novel CSF biomarkers for frontotemporal lobar degenerations

Neurology

Volumn 75, Issue 23, 2010, Pages 2079-2086

  Hu, W T ^a,b,e   Chen Plotkin, A ^a,b   Grossman, M ^a   Arnold, S E ^a   Clark, C M ^a   Shaw, L M ^c   McCluskey, L ^a   Elman, L ^a   Hurtig, H I ^a   Siderowf, A ^a   Lee, V M Y ^b,c   Soares, H ^d   Trojanowski, J Q ^b,c  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Laboratory Medicine   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; ANGIOPOIETIN 2; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CORTICOTROPIN; EOTAXIN 3; FAS ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 23; MACROPHAGE DERIVED CHEMOKINE; PROTEIN S100B; TAR DNA BINDING PROTEIN; TAU PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SEMANTIC DEMENTIA; SENSITIVITY AND SPECIFICITY;

EID: 77956226049     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318200d78d     Document Type: Article

References (36)

1. McKhann GM, Albert MS, Grossman M, Miller B, Dick-son D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803-1809.
2. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropatho-logic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Fron-totemporal Lobar Degeneration. Acta Neuropathol 2007; 114:5-22.
3. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuro-pathol 2009;117:15-18.
4. Josephs KA, Petersen RC, Knopman DS, et al. Clinico-pathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66:41-48.
5. Hu WT, Mandrekar JN, Parisi JE, et al. Clinical features of pathologic subtypes of behavioral-variant frontotemporal dementia. Arch Neurol 2007;64:1611-1616.
6. Grossman M, Xie SX, Libon DJ, et al. Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology 2008;70:2036-2045.
7. Whitwell JL, Jack CR Jr, Senjem ML, et al. MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. Neurodegener Dis 2009;6:106-117.
8. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007;6: 295-303.
9. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403-413.
10. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid /3-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-389.
11. Foulds P, McAuley E, Gibbons L, et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neu-ropathol 2008;116:141-146.
12. Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008;65:1481-1487.
13. Hu WT, Chen-Plotkin A, Arnold SE, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010;119:669-678.
14. Hu WT, Chen-Plotkin A, Arnold SE, et al. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol 2010;120:385-399.
15. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.
16. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
17. Ross MA, Miller RG, Berchert L, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria: rhCNTF ALS Study Group. Neurology 1998;50:768-772.
18. Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009;117:137-149.
19. Litvan I, Bhatia KP, Burn DJ, et al. Mov Disord Society Scientific Issues Committee report: SIC Task Force ap-praisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-486.
20. Hu WT, Seelaar H, Josephs KA, et al. Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol 2009;66:1359-1364.
21. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009;5:325-331.
22. Kasai T, Tokuda T, Ishigami N, et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 2009;117:55-62.
23. Mitchell RM, Freeman WM, Randazzo WT, et al. A CSF biomarker panel for identification of patients with amyo-trophic lateral sclerosis. Neurology 2009;72:14-19.
24. Kuhle J, Lindberg RL, Regeniter A, et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol 2009;16:771-774.
25. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007;14:1329-1333.
26. Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006;66: 1218-1222.
27. Bilic E, Bilic E, Rudan I, et al. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls Eur J Neurol 2006;13:1340-1345.
28. Brettschneider J, Widl K, Ehrenreich H, Riepe M, Tu-mani H. Erythropoietin in the cerebrospinal fluid in neu-rodegenerative diseases. Neurosci Lett 2006;404:347-351.
29. Kawajiri M, Mogi M, Higaki N, et al. Reduced angioten-sin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 119:341-344.
30. Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 2010; 16:142-145.
31. Schaub FJ, Han DK, Liles WC, et al. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 2000;6:790-796.
32. Kling AS, Tachiki K, Lloyd R. Neurochemical correlates of the Kluver-Bucy syndrome by in vivo microdialysis in monkey. Behav Brain Res 1993;56:161-170.
33. Kebir H, Ifergan I, Alvarez JI, et al. Preferential recruitment of interferon-gamma-expressing T H 17 cells in multiple sclerosis. Ann Neurol 2009;66:390-402.
34. Kawanokuchi J, Shimizu K, Nitta A, et al. Production and functions of IL-17 in microglia. J Neuroimmunol 2008;194:54-61.
35. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006;59:952-962.
36. Hodges JR, Davies RR, Xuereb JH, et al. Clinicopatholog-ical correlates in frontotemporal dementia. Ann Neurol 2004;56:399-406.